Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 02, 2025 04:59 ET | Source: Vanotech Ltd

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration

Chengdu Origen and Vanotech Announce First Patient Dosed in VAN-2401 Phase 1 Trial of Gene Therapy for Wet Age-Related Macular Degeneration
March 12, 2025 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update on Thursday, March 27, 2025

ALPHARETTA, Ga., March 12, 2025 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD) (“Clearside” or the “Company”), a biopharmaceutical company revolutionizing the delivery of therapies to...
January 28, 2025 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Multiple Medical Meeting Presentations Focused on the Advantages of Suprachoroidal Delivery and Key Differentiators in its CLS-AX Clinical Program

- Upcoming Presentations at Angiogenesis and Macula Society Conferences to Feature CLS-AX Sub-Group Analyses from ODYSSEY Wet AMD Trial - - CLS-AX Targets Flexible Dosing of Biologics with Duration...
January 22, 2025 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces its Asia-Pacific Partner, Arctic Vision, Received Approval of Suprachoroidal Treatment for Uveitic Macular Edema in Australia and Singapore

- ARCATUS®, Branded as XIPERE® in the U.S., is the First Globally Approved Suprachoroidal Therapy - - Continued Global Expansion of Clearside’s Suprachoroidal Space Injection Platform Featuring...
June 12, 2024 07:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical’s Leadership in Suprachoroidal Delivery Featured in Multiple Presentations at the Clinical Trials at the Summit Meeting

- Broad Use of Suprachoroidal Injection Platform Highlighted Across Retinal Indications - - Robust Safety Profile and Encouraging Efficacy Data Reported Utilizing SCS Microinjector® - ...
March 09, 2023 16:05 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

- Initiation of Phase 2b ODYSSEY Trial of CLS-AX in Wet AMD Expected in Q2 2023 - - Medical Meeting Presentations Highlight Significant Potential of CLS-AX Based on Positive OASIS Phase 1/2a Safety...
September 11, 2020 08:30 ET | Source: Clearside Biomedical, Inc.

Clearside Biomedical’s Oncology Licensing Partner Doses First Patient in its Phase 2 Study in Patients with Choroidal Melanoma Using SCS Microinjector® for Suprachoroidal Delivery

ALPHARETTA, Ga., Sept. 11, 2020 (GLOBE NEWSWIRE) -- Clearside Biomedical, Inc. (Nasdaq: CLSD), a biopharmaceutical company dedicated to developing and delivering treatments that restore and preserve...
November 13, 2012 13:00 ET | Source: Transcend Medical

Transcend Medical Announces 12-Month European Study Results of the CyPass Micro-Stent(R) at AAO 2012

CHICAGO, IL--(Marketwire - Nov 13, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced the 12-month results of the...
November 12, 2012 09:00 ET | Source: Transcend Medical

Transcend Medical Launches the Transcend Vold Gonio Lens (TVG) for Improved Visualization During Micro-Invasive Glaucoma Surgery

CHICAGO, IL--(Marketwire - Nov 12, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, today announced the commercial...
April 21, 2012 09:00 ET | Source: Transcend Medical

Transcend Medical Announces Four Scientific Abstracts at the American Society of Cataract and Refractive Surgery Annual Meeting

CHICAGO, IL--(Marketwire - Apr 21, 2012) - Transcend Medical, Inc., an ophthalmic device company dedicated to developing minimally invasive glaucoma therapies, announced that the CyPass...